Pharmaceutical Business review

Mylan, Roche resolve cancer drug patent dispute

Xeloda Tablets, 150mg and 500mg, USP are indicated as a treatment of metastatic breast and colorectal cancers.

Pursuant to the agreement, the litigation was dismissed on 21 September 2011.

Further, the terms of the agreement were not disclosed.